Because tPA thrombolytic therapy after stroke can increase the permeability of the BBB as well as the risk of hemorrhage transformation, inhibition of VEGF induction has broad application prospects after delayed tPA treatment. The gene discussed is VEGFA; the disease is stroke disorder.